Investigating how LAG3 and PD-1 work together in melanoma treatment
Project 1: Evaluating the synergy of LAG3 and PD-1 in melanoma patients
This study is looking at how two proteins, LAG3 and PD-1, affect the immune system in melanoma patients who might not be responding to current treatments, and it will test different therapies to see if they can help improve the immune response and fight the cancer better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10926839 on NIH RePORTER |
What this research studies
This research focuses on understanding the roles of two immune checkpoint proteins, LAG3 and PD-1, in melanoma patients who may not respond to current immunotherapies. By examining how these proteins affect the immune response, particularly in CD8+ T cells, the study aims to identify potential new treatment strategies. The research includes a clinical trial where patients will receive either anti-PD1, anti-LAG3, or a combination of both therapies to evaluate their effectiveness. Patients will be monitored for changes in their immune response and tumor progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have previously failed immunotherapy treatments.
Not a fit: Patients with early-stage melanoma or those who have not undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for melanoma patients who currently do not respond to existing therapies.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting immune checkpoints in cancer treatment.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Vignali, Dario Aa — University of Pittsburgh at Pittsburgh
- Study coordinator: Vignali, Dario Aa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.